Brief: HLS Therapeutics Announces Q4, Fiscal 2021 Financial Results
March 17 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q4 AND FISCAL 2021 FINANCIAL
RESULTS
* Q4 2021 REVENUE WAS $15.7 MILLION COMPARED TO $16.5
MILLION IN
Q4 2020
* QTRLY LOSS PER SHARE $0.13
* Q4 EARNINGS PER SHARE VIEW $-0.10, REVENUE VIEW $16.7
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nCNWvQ5Rja
Further company coverage: HLS.TO
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease